Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs

Enhance your knowledge of approved and investigational antibody–drug conjugates targeting HER2, HER3, TROP2, or B7-H3 in lung cancer, including the differences in ADC characteristics, the latest efficacy and safety data, and strategies for optimal patient selection, through an on-demand webcast with accompanying slides and a ClinicalThought commentary.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.